Skip to main content
INNOVA CAPTAB LIMITED logo

INNOVA CAPTAB LIMITED — Investor Relations & Filings

Ticker · INNOVACAP ISIN · INE0DUT01020 LEI · 549300SNL5HFUHE66804 BSE.NS Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2024-05-20 Call Transcript
Country IN India
Listing BSE.NS INNOVACAP

About INNOVA CAPTAB LIMITED

https://www.innovacaptab.com

Innova Captab Limited is an integrated pharmaceutical company focused on the research, development, manufacturing, and marketing of a wide range of pharmaceutical formulations. The company operates primarily as a Contract Development and Manufacturing Organization (CDMO), providing comprehensive services to leading domestic and international pharmaceutical brands. Its product portfolio includes diverse dosage forms such as tablets, capsules, dry syrups, ointments, and injections across multiple therapeutic areas, including anti-infectives, analgesics, and gastrointestinal treatments. Innova Captab maintains a strong emphasis on R&D and quality control, operating advanced manufacturing facilities that adhere to global regulatory standards. In addition to its CDMO business, the company manages a domestic branded generics division and an international export business, catering to a global clientele with a focus on high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 70% confidence The document is a formal communication from Innova Captab Limited to stock exchanges (BSE and NSE) informing about the schedule of an analyst/institutional investor meeting. It specifically mentions an earnings call to discuss operational and financial performance for Q4 and FY24. The document includes details about the date, time, mode of meeting, and participants. The length of the document is 2678 characters, which is relatively short and primarily serves as an invitation and notification of the earnings call event rather than containing actual financial results or detailed analysis. Therefore, this document is not the earnings release itself but an announcement of the earnings call event. According to the classification rules, such documents are best classified as Call Transcript (CT) only if they contain the full transcript, which this does not. It is also not a Report Publication Announcement (RPA) because it does not announce the release of a report but rather the scheduling of a call. The best fit is Call Transcript (CT) category since it is an earnings call invite and related information, which is part of the earnings call process. However, since it is only an invitation and schedule notice without transcript, the closest category is Regulatory Filings (RNS) as a fallback for miscellaneous regulatory announcements that do not fit other categories. But given the document's nature as an earnings call invite, the most appropriate classification is Call Transcript (CT) with moderate confidence.
2024-05-20 English
Board Meeting — Financial Results/Other business matters
Board/Management Information Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about a scheduled Board Meeting to consider and approve the audited financial results for the quarter and year ended March 31, 2024. It is an intimation of an upcoming event rather than the financial results report itself. The document is short (2045 characters) and serves as a notification under SEBI regulations. It does not contain any financial data or detailed report content. Therefore, it is an announcement related to management/board activities, specifically a Board Meeting notice under regulatory requirements. This fits best under Board/Management Information (MANG).
2024-05-20 English
Monitoring Agency Report
Regulatory Filings Classification · 95% confidence The document is a Monitoring Agency Report for the quarter ended March 31, 2024, related to the utilization of IPO proceeds by Innova Captab Limited. It is issued pursuant to SEBI regulations concerning the monitoring of IPO proceeds. The report includes detailed information on the use of funds, certifications, and comments from the monitoring agency and the board of directors. It is not a full annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory compliance report specifically monitoring IPO proceeds utilization, which fits best under the category of Regulatory Filings (RNS) as it is a regulatory compliance document and does not fit other more specific categories like Annual Report or Interim Report. The document length is substantial and contains detailed content, so it is not merely an announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-05-09 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2024-04-24 English
Updates
Capital/Financing Update Classification · 95% confidence The document is an intimation under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It informs about a material subsidiary's board meeting approval and subsequent agreement to purchase land. The document includes details of the transaction such as date, location, consideration, and related party status. It is an announcement of a corporate event related to asset acquisition and does not contain financial statements or detailed financial analysis. The document length is 4363 characters, which is relatively short and primarily serves as a regulatory disclosure. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to a significant capital asset purchase by a subsidiary, which impacts the company's capital structure and operations.
2024-04-10 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2024. It is addressed to stock exchanges and confirms no requests for dematerialization/rematerialization of shares were received during the quarter. The document is short (2455 characters) and primarily serves as a regulatory compliance certificate rather than a financial report or announcement of a report. It does not contain financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance documents and certifications that do not fit other specific categories.
2024-04-05 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.